Content News and Resources

Dr. Falk Pharma GmbH has signed a strategic agreement with Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. and its affiliate Allianthera Boston, Inc. to co-develop ATB102, a novel aryl hydrocarbon receptor (AhR) agonist, for the treatment of inflammatory bowel disease (IBD), with

BioDuro, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has formed a strategic partnership with Atombeat Inc., a specialist in AI-driven drug discovery. The companies will collaborate to develop an AI-powered platform designed to accelerate peptide drug discovery across

Sandoz, a global player in generic and biosimilar medicines, has signed a non-binding term sheet with Evotec SE to potentially acquire Just–Evotec Biologics EU SAS. The proposed deal, valued at around USD 300 million, includes the biologics development and manufacturing

Phlow Corp., a pharmaceutical CDMO based in the United States, has announced an ongoing partnership with Antheia to domestically manufacture essential medicine components. The collaboration aims to establish a more resilient and efficient pharmaceutical supply chain through the onshoring of

AGC Biologics has announced a new agreement with Valneva SE to provide development and manufacturing services for a four-valent Shigella bioconjugate vaccine candidate. The work will be carried out at the CDMO’s facility in Heidelberg, Germany. The investigational vaccine, which

Cellipont Bioservices, a cell therapy CDMO, has announced an expanded collaboration with CellVax Therapeutics Inc., a clinical-stage biotechnology company developing personalised immunotherapies. The agreement builds on existing work around FK-PC101, currently in Phase II trials for high-risk prostate cancer, and

Quasar Medical has announced the opening of its Global Headquarters in Singapore, marking a strategic relocation from its original base in Hong Kong. The move strengthens the company’s position within Asia’s growing MedTech ecosystem. The new facility, located in Singapore’s

WuXi Biologics has commenced construction of a new modular Drug Product (DP) facility in Singapore as part of its expanding CRDMO hub in the region. The site will cover approximately 30,000 square metres and is being built in collaboration with

Diorasis Therapeutics has announced a strategic partnership with Northway Biotech, a contract development and manufacturing organisation (CDMO), to establish a scalable current Good Manufacturing Practice (cGMP) process for its lead gene therapy candidate in open-angle glaucoma. The collaboration will support